ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

HYL Hyloris Pharmaceuticals SA

11.70
0.00 (0.00%)
21 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Hyloris Pharmaceuticals SA EU:HYL Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 11.70 11.90 13.00 0.00 16:40:00

EMM Disclosure

01/08/2003 10:36am

UK Regulatory


RNS Number:2323O
Deutsche Bank AG London
01 August 2003

                                 EMM DISCLOSURE

                                                             FORM 38.5 (SUMMARY)

Lodge with a RIS and the Takeover Panel. Use a separate form for each class of
securities in which dealings have been made.



CONNECTED EXEMPT MARKET- MAKERS:
DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS



Name of EMM Deutsche Bank AG London




Date of disclosure 01/08/03




Contact name Kelly-Jade Ledwich




Telephone number 0207 545 7804




Please see attached disclosure of dealings under Rule 38.5 in the securities
of the following companies:

Hamleys Plc



AMENDMENT

If the attached Rule 38.5 disclosure is to amend a previous disclosure, please
state which element(s) of previous disclosure was incorrect:




In the case of option business or dealings in derivatives full details should be
given on a separate sheet so that the nature of the dealings can be fully
understood. For options this should include the number of securities under
option, the exercise period (or in the case of exercise, the exercise date), the
exercise price and any option money paid or received. For derivatives this
should include, at least, the number of reference securities to which they
relate (when relevant), the maturity date (or if applicable the closing out
date) and the reference price.

For full details of the disclosure requirements see Rules 8 and 38 of the Code.
If in doubt contact the Monitoring Section of the Panel, Tel. No: 020 7638 0129.
Email: monitoring@disclosure.org.uk

                                                                       FORM 38.5

CONNECTED EXEMPT MARKET-MAKERS:

DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS

Dealing in (name of company) Hamleys Plc




Class of security Ordinary




Date of disclosure 01/08/03




Date of dealing 31/07/03




Name of EMM Deutsche Bank AG London




Name of offeree/offeror with whom connected Hamleys Plc




Total number of securities purchased




Highest price paid* #




Lowest price paid*#




Total number of securities sold 900,000




Highest price received* #2.52




Lowest price received* #2.52




*Currency must be stated




                                                     Rule 38.5 (CFD)



            CONNECTED EXEMPT MARKET-MAKERS/EXEMPT PRINCIPAL TRADERS:

      DISCLOSURE UNDER RULE 38.5 OF THE CITY CODE ON TAKEOVERS AND MERGERS



Dealing in Contract for Differences ("CFD") referenced to .........Hamleys Plc
........................(Company)

(Class of security) ....................Ordinary....................



Date of disclosure ...............01/08/03.....................................

Date of dealing ..................31/07/03.....................................

Name of EMM/EPT...Deutsche Bank AG London.........

Name of offeree/offeror with whom connected ......Hamleys Plc..................
...............................

Product Type ..............................Long CFD...........................
........................................

Maturity Date ..................Open Ended....................................
...........................







Writing of CFD

Number of Ordinary Shares to which the CFD is referenced ............ .........
..................



CFD reference price between...............................................







Closing Out of CFD

Number of Ordinary Shares to which the CFD is referenced............900,000...
.........................



CFD closing out price ........................#2.52....... .....................
.......................






Further disclosure should be made where necessary so that the nature of the
dealings can be fully understood.








                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

EMMSSESUFSDSEDA

1 Year Hyloris Pharmaceuticals Chart

1 Year Hyloris Pharmaceuticals Chart

1 Month Hyloris Pharmaceuticals Chart

1 Month Hyloris Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock